This is the case, for example, with the estrogen receptor-α (ERα) antagonist fulvestrant and related selective ER down-regulators (SERDs) which have the capacity to modulate the tumor microenvironment via an action on myeloid-derived suppressor cells, tumor infiltrating lymphocytes, and other immune cell subpopulations. The gene discussed is ESR1; the disease is neoplasm.